Intravenous iron sucrose: Establishing a safe dose

被引:140
作者
Chandler, G
Harchowal, J
Macdougall, IC [1 ]
机构
[1] Kings Coll Hosp London, Dept Renal Med, Renal Unit, London SE22 8PT, England
[2] Kings Coll Hosp London, Dept Pharm, London SE22 8PT, England
关键词
intravenous (IV) iron; iron sucrose; safe dose; epoetin;
D O I
10.1053/ajkd.2001.28587
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
It is now recognized that the majority of patients on epoetin therapy require intravenous (IV) iron supplementation to maximize the response to treatment. Of the IV iron, preparations available, iron sucrose has proved its efficacy and safety; however, there are no guidelines or systematic studies examining the optimum safe dosage regimen for this compound. The aim of the present study was to investigate prospectively a variety of dosing regimens for IV iron sucrose in patients with renal failure to. develop treatment strategies for this preparation. A total of 335 iron infusions was administered to 249 patients in this study, which was conducted in four phases. In phase 1, 89 patients were administered a dose of 200 mg as. an IV infusion over 2 hours. No adverse events were seen. A 500-mg dose by 2-hour infusion was then assessed, but was abandoned after 8 of 22 patients developed reactions characterized by dizziness, hypotension, and nausea. The dose was then reduced to 300 mg by 2-hour infusion for the next 189 patients, and again, no, adverse reactions were witnessed. Finally, a 400-mg dose by 2-hour infusion was examined in 35 patients, but 2 patients experienced such symptoms as hypotension, nausea, and lower back pain. Both the 200- and 300-mg doses of IV Iron sucrose administered over 2 hours appear to be safe. The incidence of adverse events with the 400- and 500-mg doses administered as a 2-hour infusion seems too high to recommend their routine use, although it may be possible to administer these doses over a longer period. (C) 2001 by the National Kidney Foundation, Inc.
引用
收藏
页码:988 / 991
页数:4
相关论文
共 16 条
  • [1] ALWAKEEL JS, 1997, INDIAN J NEPHROL, V7, P91
  • [2] CAVILL I, 1982, CLIN HAEMATOL, V11, P259
  • [3] TREATMENT OF THE ANEMIA OF PROGRESSIVE RENAL-FAILURE WITH RECOMBINANT HUMAN ERYTHROPOIETIN
    ESCHBACH, JW
    KELLY, MR
    HALEY, NR
    ABELS, RI
    ADAMSON, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) : 158 - 163
  • [4] CORRECTION OF THE ANEMIA OF END-STAGE RENAL-DISEASE WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN - RESULTS OF A COMBINED PHASE-I AND PHASE-II CLINICAL-TRIAL
    ESCHBACH, JW
    EGRIE, JC
    DOWNING, MR
    BROWNE, JK
    ADAMSON, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (02) : 73 - 78
  • [5] The safety of intravenous iron dextran in hemodialysis patients
    Fishbane, S
    Ungureanu, VD
    Maesaka, JK
    Kaupke, CJ
    Lim, V
    Wish, J
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 28 (04) : 529 - 534
  • [6] INTRAVENOUS IRON DEXTRAN IN CLINICAL MEDICINE
    HAMSTRA, RD
    BLOCK, MH
    SCHOCKET, AL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1980, 243 (17): : 1726 - 1731
  • [7] Strategies for iron supplementation: Oral versus intravenous
    Macdougall, IC
    [J]. KIDNEY INTERNATIONAL, 1999, 55 : S61 - S66
  • [8] Intravenous administration of iron in epoetin-treated haemodialysis patients - which drugs, which regimen?
    Macdougall, IC
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (11) : 1743 - 1745
  • [9] Macdougall IC, 1997, J AM SOC NEPHROL, V8, pA1020
  • [10] Seligman PA, 1999, CLIN CHEM, V45, P898